Two-Year Results of a Treat and Extend Regimen with Aflibercept in Caucasian Patients with Pachychoroid Neovasculopathy

There are few reports evaluating the treatment of pachychoroid neovasculopathy (PNV) in white patients. The purpose of this study is to analyze the results of a treat and extend regimen with aflibercept in white patients with PNV after 2 years of follow-up. We performed a retrospective study in 31 e...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in ophthalmology 2023-05, Vol.38 (4), p.352-357
Main Authors: Montero Hernández, Javier, Remolí Sargues, Lidia, Monferrer Adsuara, Clara, Castro Navarro, Verónica, Navarro Palop, Catalina, Cervera Taulet, Enrique
Format: Article
Language:English
Subjects:
Aged
Choroidal Neovascularization - therapy
Female
Humans
Intravitreal aflibercept
Intravitreal Injections
Macula Lutea
Male
Middle Aged
optical coherence tomography
pachychoroid disease
pachychoroid neovasculopathy
Receptors, Vascular Endothelial Growth Factor - therapeutic use
Recombinant Fusion Proteins - therapeutic use
Retrospective Studies
Subretinal Fluid
treat and extend regimen
Visual Acuity
White People
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There are few reports evaluating the treatment of pachychoroid neovasculopathy (PNV) in white patients. The purpose of this study is to analyze the results of a treat and extend regimen with aflibercept in white patients with PNV after 2 years of follow-up. We performed a retrospective study in 31 eyes of 26 patients with PNV treated with a treat an extend regimen of intravitreal aflibercept. The mean age was 63,84 ± 7.92 years. There were 9 males (35%) and 17 females (65%). Best-corrected visual acuity (BCVA), central macular thickness (CMT), choroidal subfoveal thickness (CST), choroidal thickness (CT) under type 1 choroidal neovascularization (CNV), pigment epithelium detachment (PED) height, and presence of subretinal fluid (SRF), intraretinal fluid (IRF) and wet macula, were evaluated at baseline and after 3, 6, 12, and 24 months. BCVA remained stable during the follow-up (p 0.161). A significant diminution of CMT was found (p 0.001). Conversely, PED height diminution was not significative (p 0.260). CST and CT under type 1 CNV improved significantly during the follow-up (p 0.005 and 0.009, respectively). Also, wet macula improved after 24 months (p 
ISSN:0882-0538
1744-5205
DOI:10.1080/08820538.2023.2194983